WEST PHARMACEUTICAL SERVICES

West Pharmaceutical Services will release Q3‑2026 results before the market opens on Oct. 29, offering investors early insight into its injectable drug‑delivery growth and strategy.

Discover how West Pharmaceutical’s SelfDose® platform will reshape injectable drug delivery at CPHI 2026, boosting patient adherence, reducing costs, and unlocking new market growth.

West Pharmaceutical Services officer update: minor share change, phantom‑stock plan, no dilution impact, but financial, supply‑chain and tech‑investment challenges outlined.

West Pharmaceutical Services expands U.S. capacity, driving 18% growth in high‑margin syringe and pen sales for GLP‑1 and biologic therapies. Learn how its capital strategy, regulatory focus, and risk management position it for continued success in …

West Pharmaceutical Services’ share price fell 26% over five years due to slower growth, rising capex and regulatory costs. Explore how mRNA expansion and service diversification could reverse the trend.

West Pharmaceutical Services CFO’s Form 4 filing shows a modest net rise in ownership after share trades and RSU conversions, highlighting insider confidence and SEC‑compliant governance.

West Pharmaceutical Services cyber‑breach reveals the growing risk to pharma data security—why operational resilience, IP protection, and strategic M&A matter for industry survival.

West Pharmaceutical Services shines in income‑focused ETFs, delivering stable dividends and cutting‑edge drug delivery tech for biopharma.

West Pharmaceutical Services Q2 2026: modest sales growth, $210 M operating income, and a $112 M AbbVie sale boosting cash & future innovation.

West Pharmaceutical Services Q2 2026: $800 M net sales, $2.00+ EPS, strong cash flow, and a mid‑$3 B sales outlook driven by high‑growth injectable drug demand.